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Abstract. MicroRNAs (miRNAs) play a key role in cancer 
pathogenesis and are involved in several human cancers, 
including non-small cell lung cancer (NSCLC). This study 
evaluated Let-7g and miR-21 expression by quantitative real-
time PCR in 80 NSCLC patients and correlated the results with 
their main clinicopathological and molecular features. MiR-21 
expression was significantly higher in NSCLC tissues compared 
to non-cancer lung tissues (p<0.0001), while no significant 
changes in Let-7g expression were observed between the tumor 
and normal lung tissues. Target prediction analysis led to the 
identification of 26 miR-21 and 24 Let-7g putative target genes 
that play important roles in cancer pathogenesis and progression. 
No significant association was observed between the analysed 
miRNAs and the main clinicopathological or molecular char-
acteristics of the NSCLC patients, although both miRNAs 
were downregulated in squamous cell carcinomas compared to 
adenocarcinomas. Noteworthy, we observed a significant asso-
ciation between low Let-7g expression and metastatic lymph 
nodes at diagnosis (p=0.046), as well as between high miR-21 
expression and K-Ras mutations (p=0.0003). Survival analysis 
did not show any significant correlation between prognosis and 
the analysed miRNAs, although the patients with a high Let-7g 
and miR-21 expression showed a significantly lower short-term 
progression-free survival (p=0.01 and p=0.0003, respectively) 
and overall survival (p=0.023 and p=0.0045, respectively). In 
conclusion, we showed that Let-7g and miR-21 expression was 
deregulated in NSCLC and we demonstrated a strong relation-
ship between miR-21 overexpression and K-Ras mutations. 
Our data indicate that Let-7g and miR-21 profiling combined 
with the determination of K-Ras mutational status may be 
considered a useful biomarker for a more effective molecular 
characterization and clinical management of NSCLC patients.
Introduction
Lung cancer is the leading cause of cancer-related mortality 
worldwide (1) and 85% of the cases are represented by non-
small cell lung cancer (NSCLC), which is classified into 
three different histological subtypes: adenocarcinoma (ADC), 
squamous cell carcinoma (SCC) and large cell carcinoma 
(LCC) (2-4). Despite a better understanding of the NSCLC 
pathogenesis and significant improvement in early diagnosis 
and treatment, the overall 5-year survival is extremely low 
(~15%) and the patients show high recurrence rates even at 
the early disease stages (1-7), highlighting the necessity of a 
deeper knowledge of NSCLC biology and the identification of 
more effective biomarkers.
MicroRNAs (miRNAs) are a highly conserved family of 
small (17-22 nucleotides), non-coding, endogenous, single-
stranded RNA molecules that negatively regulate gene 
expression by binding to complementary sequences on target 
messenger RNA (mRNA) (8,9). Recently, miRNAs have been 
shown to regulate essential cell processes, such as cell prolif-
eration, differentiation, apoptosis, development and metabolism 
(9-11), and to play a key role in cancer pathogenesis (12-16). 
Moreover, a miRNA prognostic and diagnostic value has been 
reported in several malignancies, including lung cancer (14-16).
The first reported miRNA aberrantly expressed in lung 
cancer was the Let-7 family (17). A reduced Let-7 expression 
has been significantly correlated with a short post-operative 
survival in the NSCLC patients (17). Moreover, the ectopic 
Let-7 expression inhibits cell proliferation in human NSCLC 
cell lines (18) and reduces tumor burden in mouse NSCLC 
xenografts (19). Let-7 family members have been demonstrated 
to behave as tumor suppressor genes and to functionally inhibit 
several cell cycle regulators and oncogenes, such as Ras family, 
c-Myc and HMGA2 genes, whose 3'UTRs show multiple Let-7 
binding sites (13,20,21).
Conversely, a role as oncogene has been suggested for 
miR-21 that is deregulated in glioblastoma and lung cancer 
(22-25). A miR-21 overexpression has been suggested to be an 
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independent negative prognostic factor for the overall survival 
in NSCLC patients (23) and to be related to the lung carci-
nogenesis in never smokers (26). Several mRNAs have been 
identified as miR-21 targets, including PDCD4, PTEN, TGF-β 
and MMP9 genes (22,27).
The aim of this study was to evaluate Let-7g and miR-21 
expression in a series of 80 NSCLC patients to establish their 
involvement in the NSCLC pathogenesis and their potential 
diagnostic, prognostic and predictive value.
Materials and methods
Patients. Eighty NSCLC patients were retrospectively selected 
from patients who had undergone surgery at the Unit of 
Thoracic Surgery of the A.O.U.P. between 2005 and 2012. 
Histological diagnoses were independently formulated by two 
pathologists (G.F. and G.A.) according to the World Health 
Organization classification (2-4) and discrepant diagnoses were 
re-evaluated and discussed until an agreement was reached. 
Clinicopathological characteristics were collected whenever 
available for all the patients, while detailed clinical data were 
obtained only for 55 patients. The study was approved by the 
local Ethics Committee and all the patients gave their informed 
consent to the molecular analyses.
DNA and RNA isolation. DNA and RNA were isolated from 
10-µm sections of formalin-fixed and paraffin-embedded 
(FFPE) tissues or cytological specimens after manual tumor 
macrodissection using the QIAamp DNA Mini kit (Qiagen) 
and miRNeasy FFPE kit (Qiagen), respectively, according to 
the manufacturer's instructions.
MiRNA expression. Quantification of Let-7g, miR-21 and RNU6B 
expression was carried out in triplicate into 80 NSCLC and 
27 non-cancer lung tissues using specific TaqMan® MicroRNA 
assays (Applied Biosystems) according to the manufacturer's 
instructions. Briefly, 10 ng of total RNA were retro-transcribed 
by the TaqMan MicroRNA Reverse Transcription (RT) kit 
(Applied Biosystems) and 1.3 µl of RT product were analysed by 
quantitative real-time PCR (qRT-PCR) on the Rotor-Gene 6000 
(Corbett Research). Threshold cycle (Ct) and baselines were 
determined by manual settings. MiRNA expression was calcu-
lated by relative quantification and fold expression changes 
were determined by the 2-∆∆Ct method using the DataAssist™ 
software (Applied Biosystems).
Target prediction and pathway analysis. Let-7g and miR-21 
target genes were predicted by four different miRNA target 
prediction algorithms: miRanda (http://www.microrna.org/
microrna), TargetScan (http://www.targetscan.org), Pictar 
(http://www.pictar.org) and miRDB (http://www.mirdb.
org). Gene ontology classification and pathway analysis were 
performed using the PANTHER software (http://www.pant-
herdb.org).
Mutational analysis. K-Ras gene (Reference sequence: 
ENSG00000133703) status in codons 12 and 13 was analyzed 
by pyrosequencing using the Anti-EGFR MoAb response® kit 
(K-Ras status) (Diatech Pharmacogenetics) according to the 
manufacturer's instructions.
PCR-single stranded conformation polymorphism 
(PCR-SSCP) and sequencing analysis were used for geno-
typing exons 18-21 of the EGFR gene (Reference sequence: 
ENSG00000146648). The primer sequences were as follows: 
exon 18, 5'-CTCTGTGTTCTTGTCCCCCC-3' (forward) and 
5'-GCCTGTGCCAGGGACCTTAC-3' (reverse); exon 19, 
5'-CATGTGGCACCATCTCACA-3' (forward) and 5'-CCACA 
CAGCAAAGCAGAAAC-3' (reverse); exon 20, 5'-CACACTG 
ACGTGCCTCTCC-3' (forward) and 5'-TATCTCCCCT 
CCCCGTATCT-3' (reverse); exon 21, 5'-CCTCACAGCAGG 
GTCTTCTC-3' (forward) and 5'-CCTGGTGTCAGGAAA 
ATGCT-3' (reverse). Briefly, 100 ng of DNA were amplified by 
PCR using the FastStart Taq DNA Polymerase (Roche 
Diagnostics) on the T3000 Thermocycler 48 (Biometra), as 
follows: 4 min at 95˚C, 40 cycles at 95˚C for 30 sec, 58˚C for 
30 sec and 72˚C for 45 sec and 10 min at 72˚C. PCR products 
were mixed with an equivalent formamide volume, denatured at 
95˚C for 5 min and run onto a non-denaturing 12.5% polyacryl-
amide gel (GE Healthcare) at 18˚C and constant 25 mA for 1 h 
and 40 min. Denaturated DNA was visualized by the PlusOne 
DNA silver staining kit (GE Healthcare) and samples with altered 
mobility patterns were sequenced as previously described (28).
Statistical analysis. One-way analysis of variance and χ2 test 
were used to determine the association between miRNA 
expression and the different parameters, while survival anal-
ysis was performed by the Kaplan-Meier method. Statistical 
analyses were performed using the JMP10 software (SAS) and 
a two-tailed p<0.05 was considered statistically significant.
Results
Patient characteristics. This study was conducted in 
80 patients with NSCLC, including 55 ADCs, 21 SCCs, 
2 LCCs and 2 undifferentiated NSCLCs. The median age at 
diagnosis was 67 years (range 46-85) and the median follow-up 
was 32 months (range 7-98). Disease progression with distant 
and/or loco-regional recurrence and death from lung cancer 
were observed in 34 (61.8%) and 14 (25.5%) of the 55 NSCLC 
patients, respectively. The median progression-free survival 
(PFS) and overall survival (OS) were 18 months (95% CI, 
14-24) and 24 months (95% CI, 18-30), respectively.
Let-7g and miR-21 expression profile. We quantified the 
mature Let-7g and miR-21 expression normalized to the 
RNU6B endogenous control in 80 NSCLC and 27 non-cancer 
lung tissues. The unsupervised hierarchical clustering analysis 
of miRNA expression using the Euclidean distance as a simi-
larity measure and average linkage algorithm revealed two 
major clusters based on similarities in miR-21 expression that 
clearly separated the tumor from non-cancer tissues. On the 
contrary, we did not observe a clear separation between tumor 
and normal samples based on Let-7g expression (Fig. 1A).
Let-7g was barely detectable in lung tissues and we did 
not observe any significant difference between the NSCLC 
and normal samples (-0.897±0.148 vs. -0.709±0.168, p=0.585, 
Fig. 1B). Conversely, a highly significant increase in miR-21 
expression was observed in the NSCLC tissues compared to 
the non-cancer ones (4.842±0.163 vs. 2.509±0.182, p<0.0001, 
Fig. 1C).
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MiRNA profile and clinicopathological characteristics. To 
determine whether miRNA profile was correlated with the 
main clinicopathological characteristics, the NSCLC patients 
were divided into Let-7g and miR-21 high and low expression 
groups based on the median fold-change values (1.315±0.175 
for Let-7g and 6.964±0.759 for miR-21). Except for a significant 
association between the low Let-7g expression and metastatic 
lymph node presence at diagnosis (p=0.046), no other statis-
tically significant associations were observed between the 
analysed miRNA and the main clinicopathological charac-
teristics of the NSCLC patients (Table I). Interestingly, both 
Let-7g and miR-21 were upregulated in ADCs compared to 
SCCs, although these relationships were not statistically 
significant (Fig. 2A and B).
Figure 1. Let-7g and miR-21 expression. (A) Unsupervised hierarchical cluster analysis of miRNA expression in NSCLC tissues (AD samples) versus non-cancer 
lung tissues (N samples). Box and Whisker plots of Let-7g (B) and miR-21 (C) expression in NSCLC tissues compared to non-cancer lung tissues. Values of 
Let-7g and miR-21 expression normalized to RNU6B endogenous control are reported as Log22-∆Ct.
Figure 2. Box and Whisker plots of the differential Let-7g (A) and miR-21 (B and C) expression in relation to the main NSCLC histological subtypes (A and B) 
and K-Ras mutational status (C) in the NSCLC patients. Values of Let-7g and miR-21 expression are reported as fold-change of the target miRNA relative 
expression relatively to a pool of non-cancer lung tissues after normalization to the endogenous control RNU6B.
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MiRNA profile and K-Ras and EGFR status. To investigate 
whether Let-7g and miR-21 expression was correlated to K-Ras 
and EGFR mutational status, we performed genotyping in the 
80 NSCLC patients, except 2, due to insufficient tissue. K-Ras 
and EGFR mutations were observed in 16 (20.5%) and 23 
(29.5%) of the 78 NSCLC patients, respectively (Table II).
K-Ras and EGFR mutations were mutually exclusive, 
observed only in the NSCLC patients with ADC and associ-
ated with gender (Table III). As is shown in Table III, EGFR 
status was also significantly associated with the smoking habit 
(p=0.0086), performance status (p=0.0008) and response to 
the treatment with EGFR tyrosine kinase inhibitors (TKIs) 
(p=0.0076).
Statistical analysis did not show any significant association 
between EGFR mutations and Let-7g or miR-21 expression, 
while we found a highly significant association between 
Table I. Correlations between the Let-7g and miR-21 expression and the main clinicopathological characteristics of the NSCLC 
patients.
 Let-7g expressiona miR-21 expressiona ---------------------------------------------------- ---------------------------------------------------
Characteristic Low High p-valueb Low High p-valueb
Age
 ≤67 years 22 (57.9) 16 (42.1) 0.263 19    (50) 19    (50) 0.823
 >67 years 18 (42.8) 24 (57.2)  21    (50) 21    (50)
Gender
 Males 28 (50.9) 27 (49.1) 0.809 27 (49.1) 28 (50.9) 0.809
 Females 12    (48) 13    (52)  13    (52) 12    (48)
Histology
 ADC 27 (49.1) 28 (50.9) 0.157 24 (43.6) 31 (56.4) 0.065
 SCC 13 (61.9)   8 (38.1)  14 (66.7)   7 (33.3)
 LCC   0      (0)   2  (100)    2  (100)   0      (0)
 Others   0      (0)   2  (100)    0      (0)   2  (100)
Tumor stage
 T1 (T1a-T1b)   6    (50)   6    (50) 0.111   5 (41.7)   7 (58.3) 0.793
 T2 (T2a-T2b) 16 (51.6) 15 (48.4)  13 (41.9) 18 (58.1)
 T3   2 (14.3) 12 (85.7)    8 (57.2)    6 (42.8)
 T4   3    (50)   3    (50)    3    (50)   3    (50)
Lymph node status
 Negative   4 (21.1) 15 (78.9) 0.046   9 (47.4) 10 (52.6) 0.633
 Positive 20 (52.6) 18 (47.4)  14 (36.8) 24 (63.2)
Smoking
 Never smoking   7 (53.8)   6 (46.2) 0.425   7 (53.8)   6 (46.2) 0.872
 Former smoking 17 (65.4)   9 (34.6)  16 (61.5) 10 (38.5)
 Current smoking   2  (100)   0      (0)    1    (50)   1    (50)
Performance status
 ECOG 0   5 (45.5)   6 (54.5) 0.396   5 (45.5)   6 (54.5) 0.149
 ECOG 1 20    (69)   9    (31)  18 (62.1) 11 (37.9) 
 ECOG 2   1    (50)   1    (50)    2  (100)   0      (0)
TKI response
 Complete response   1  (100)   0      (0) 0.181   1  (100)   0      (0) 0.218
 Partial response 13 (72.2)   5 (27.8)  10 (55.6)   8 (44.4)
 Stable disease   7    (70)   3    (30)    6    (60)   4    (40)
 Progressive disease   5 (55.6)   4 (44.4)    7 (77.8)   2 (22.2)
Disease recurrence
 NED 10 (47.6) 11 (52.4) 0.072   8 (38.1) 13 (61.9) 0.189
 Recurrence 20 (58.8) 14 (41.2)  21 (61.8) 13 (38.2)
aValues are shown as n (%). bp-values were assessed by χ2 test and significant p-values are in bold. ADC, adenocarcinoma; SCC, squamous 
cell carcinoma; LCC, large cell carcinoma; ECOG, Eastern Cooperative Oncology Group; TKI, tyrosine kinase inhibitor; NED, no evidence 
of disease.
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K-Ras status and miR-21 expression (p=0.0003, Table III). 
Noteworthy, a significantly higher miR-21 expression was 
observed in the NSCLC patients with K-Ras-mutated tumors 
(14.237±1.638, p<0.001) compared to the patients with K-Ras-
wild-type tumors (7.316±0.792, Fig. 2C).
miRNA target prediction and pathway analysis. Let-7g and 
miR-21 target gene analysis by miRanda, TargetScan, Pictar 
and miRDB prediction algorithms led to the identification 
of a plethora of putative target genes for these miRNAs. In 
order to minimize the number of false positives, we recorded 
a gene as a putative target gene of the analysed miRNAs only 
if it was predicted by at least two prediction algorithms with 
a high confidence score. According to these stringent criteria, 
we identified 24 putative target genes for Let-7g, including 
HMGA2, ERCC6 and MAP3K3 genes and 26 putative target 
genes for miR-21, including PDCD4, MSH2 and SPRY1/
SPRY2 genes (Table IV).
We further investigated the biological consequences of 
Let-7g and miR-21 aberrant expression grouping the predicted 
target genes by gene ontology terms. This analysis revealed 
that most of cell processes regulated by these miRNAs play a 
key role in cancer pathogenesis and are mainly involved in cell 
proliferation, apoptosis, DNA repair, cell adhesion and signal 
transduction pathways (Table IV).
Survival analysis. To evaluate the relationships of Let-7g and 
miR-21 expression with the prognosis of the NSCLC patients, 
we performed a survival analysis by the Kaplan-Meier method 
using the disease recurrence and the overall post-operative 
survival as end-points. We did not observe any significant 
difference in PFS and OS of the NSCLC patients with a high 
Let-7g or miR-21 expression compared to the patients with a 
low expression of these miRNAs (Fig. 3). However, we further 
investigated Let-7g and miR-21 as prognostic indicators by 
restricting our analysis to the first 30 months of the follow-up 
to verify a possible short-term prognostic value of Let-7g and 
miR-21 evaluation. Interestingly, we found that the NSCLC 
patients with a high Let-7g or miR-21 expression showed 
a significantly shorter mean PFS and OS compared to the 
patients with a low expression of these miRNAs (Table V).
Discussion
Lung cancer is the first cause of death for cancer worldwide 
and >80% of the cases are NSCLC (1-4). Although early 
diagnosis and patient care have greatly improved in recent 
years, most of the NSCLC patients show locally advanced or 
metastatic disease at diagnosis and their prognosis remains 
extremely poor (1-7). Currently, no appropriate diagnostic 
biomarker exists for NSCLC, highlighting the need of a better 
knowledge of its biology to improve prevention, diagnosis and 
treatment.
MiRNAs are a highly conserved family of small non-coding 
RNA molecules that negatively regulate gene expression (8,9) 
and their aberrant expression has been found to play a key role 
in pathogenesis of several malignancies, including NSCLC 
(13-16). This study was aimed to evaluate Let-7g and miR-21 
expression profile in the NSCLC patients in order to establish 
their role in NSCLC pathogenesis and their potential diag-
nostic, prognostic and predictive significance.
We demonstrated that miR-21 expression strongly differ-
entiates the NSCLC from non-cancer lung tissues, while 
we did not observe any Let-7g discriminative value. In our 
Table II. EGFR and K-Ras mutational status in the NSCLC patients.
Gene Exon ID sample Nucleotide substitution Amino acid substitution
EGFR 19 AD20, AD23, AD24, AD26, AD32, AD39 c.2235_2249del p.E746_A750
EGFR 19 AD28, AD29, AD35, AD40 c.2236_2250del p.E746_A750
EGFR 19 AD16, AD21, AD37 c.2237_2255delinsT p.E746_S752delinsV
EGFR 19 AD22 c.2239_2264delinsGCCAA p.L747_A755delinsAN
EGFR 19 AD25 c.2240_2257del p.L747_P753delinsS
EGFR 19+20 AD27 c.2235_2249del+c.2369C>T p.E746_A750+p.T790M
EGFR 20 AD41 c.2311_2312insGCGTGGACA p.D770_N771insSVD
EGFR 20 AD36 c.2353A>C p.T785P
EGFR 21 AD7 c.2570G>A p.G857E
EGFR 21 AD31, AD33, AD38, AD42 c.2573T>G p.L858R
K-Ras 2 AD9, AD10, AD15, AD17, AD18, AD44 c.34G>T p.G12C
K-Ras 2 AD65 c.34_35GG>TT p.G12F
K-Ras 2 LC1, AD19, AD45, AD46 c.35G>T p.G12V
K-Ras 2 AD1, AD14, AD62 c.35G>C p.G12A
K-Ras 2 AD61 c.35G>A p.G12D
K-Ras 2 AD43 c.37_38GG>CC p.G13P
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Table III. EGFR and K-Ras status in relation to the main clinicopathological and biological characteristics of the NSCLC 
patients.
 EGFR statusa K-Ras statusa ----------------------------------------------------- -----------------------------------------------------
Characteristic Wild-type Mutated p-valueb Wild-type Mutated  p-valueb
EGFR status
 Wild-type    39 (70.9) 16 (29.1) 0.0095
 Mutated    23  (100)   0      (0)
Age
 ≤67 years 24 (43.6) 12 (52.2)   0.6595 25 (40.3) 11 (68.8) 0.0797
 >67 years 31 (56.4) 11 (47.8)  37 (59.7)   5 (31.2)
Gender
 Males 47 (85.5)   7 (30.4) <0.0001 39 (62.9) 15 (93.8) 0.0376
 Females   8 (14.5) 16 (69.6)  23 (37.1)   1   (6.2)
Histology
 ADC 32 (58.2) 22 (95.7)   0.0049 39 (62.9) 15 (93.8) 0.0369
 SCC 20 (36.4)   0      (0)  20 (32.3)   0      (0)
 LCC   2   (3.6)   0      (0)    2   (3.2)   0      (0)
 Others   1   (1.8)   1   (4.3)    1   (1.6)   1   (6.2)
Tumor stage
 T1 (T1a-T1b)   9 (20.0)   3 (16.7)   0.1511   9 (18.4)   3 (21.4) 0.3189
 T2 (T2a-T2b) 20 (44.4) 11 (61.1)  27 (55.1)   4 (28.6)
 T3 13 (28.9)   1   (5.5)    9 (18.4)   5 (35.7)
 T4   3   (6.7)   3 (16.7)    4   (8.1)   2 (14.3)
Lymph node status
 Negative 16    (39)   3 (18.8)   0.2516 15 (34.1)   4 (30.8) 0.9111
 Positive 25    (61) 13 (81.2)  29 (65.9)   9 (69.2)
Smoking
 Never smoking   4 (15.4)   9    (60)   0.0086 12 (35.3)   1 (14.3) 0.2975
 Former smoking 21 (80.8)   5 (33.3)    21 (61.8)   5 (71.4) 
 Current smoking   1   (3.8)   1   (6.7)    1   (2.9)   1 (14.3)
Performance status
 ECOG 0   2 (18.2)   9 (81.8)   0.0008 10 (90.9)   1   (9.1) 0.5509
 ECOG 1 23 (79.3)   6 (20.7)  23 (79.3)   6 (20.7)
 ECOG 2   2  (100)   0      (0)    2  (100)   0      (0)
TKI response
 Complete response   0      (0)   1  (100)   0.0076   1  (100)   0      (0) 0.5417
 Partial response   7 (38.9) 11 (61.1)  16 (88.9)   2 (11.1)
 Stable disease   9    (90)   1    (10)    7    (70)   3    (30)
 Progressive disease   8 (88.9)   1 (11.1)    8 (88.9)   1 (11.1)
Disease recurrence
 NED 13 (35.1)   7 (41.2)   0.9016 14 (34.1)   6 (46.2) 0.6515
 Recurrence 24 (64.9) 10 (58.8)  27 (65.9)   7 (53.8)
Let-7g expression
 Low 27 (49.1) 11 (47.8)   0.8835 32 (51.6)   6 (37.5) 0.4676
 High 28 (50.9) 12 (52.2)  30 (48.4) 10 (62.5)
miR-21 expression
 Low 27 (49.1) 12 (52.2)   0.8039 38 (61.3)   1   (6.2) 0.0003
 High 28 (50.9) 11 (47.8)  24 (38.7) 15 (93.8)
aValues are shown as n (%). bp-values were assessed by χ2 test and significant p-values are in bold. ADC, adenocarcinoma; SCC, squamous 
cell carcinoma; LCC, large cell carcinoma; ECOG, Eastern Cooperative Oncology Group; TKI, tyrosine kinase inhibitor; NED, no evidence 
of disease.
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study, a highly significant increase was found in miR-21 
expression in NSCLC tissues compared to the non-cancer 
ones, in agreement with previous results that demonstrated a 
miR-21 overexpression in tumor tissues from several human 
malignancies (23,29-31). Conversely, we observed a reduced 
Let-7g expression that was expressed at comparable levels in 
NSCLC and non-cancer lung tissues. Let-7g downregulation 
in NSCLC tissues has been previously reported by several 
authors, who have also demonstrated that the aberrant expres-
sion of Let-7 family represents an early event during NSCLC 
carcinogenesis and is more common in SCCs compared 
to ADCs (12,19,32,33). In our study, Let-7g and miR-21 are 
Table IV. Putative target genes of the dysregulated Let-7g and miR-21 in the NSCLC patients.
miRNA Locus Pathway Target genes
Let-7g 3p21.1 Cell cycle HMGA2, E2F5, COIL, DNA2, CCNJ, CCND2, CDC25A, LIN28B, BACH1
  Transcription/transduction BZW1, HIC2
  DNA repair ERCC6, SMARCAD1, BACH1
  Apoptosis N-MYC, CASP3, MAP4K3
  MAPK/ERK pathway N-RAS, MAP3K3, MAP4K3, MAPK6
  Insulin/TGFβ pathway FOXP2, IGF1R, IGF2BP2
  PI3K/Akt pathway N-RAS, FOXP2, CCND2
  Wnt pathway END1, END2, N-MYC
miR-21 17q23.2 Cell cycle STAG2, KIF6
  DNA repair MSH2, FANCC, CHD7
  Apoptosis PDCD4, APAF1, STAT3, MALT1, SGK3
  Angiogenesis SOS2, JAG1, MAP3K1, STAT3
  Proteolysis WWP1
  Cell adhesion CCL1, MATN2, TGFBI, VCL
  MAPK/ERK pathway MAP3K1, STAT3, SOS2, NKIRAS1, SPRY1, SPRY2
  TGFβ pathway BMPR2, SMAD7
  G-protein pathway SOS2, TIAM2, GPR64, KRIT1
Figure 3. Kaplan-Meier curves in the NSCLC patients with a different Let-7g (A and B) and miR-21 (C and D) expression. PFS, progression-free survival; 
OS, overall survival.
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downregulated in SCCs compared to ADCs, but their evalua-
tion has not been shown to have a significant diagnostic value 
in discriminating between these two different histotypes, as 
previously reported in larger miRNA profiling studies (29,30). 
Landi et al (30) reported that Let-7g and miR-21 differential 
expression allows to discriminate between ADC and SCC in 
the early-stage tumors (stage I), but not in the advanced stage 
(stage II-IV), suggesting that miRNA expression loses its 
histology-specificity in the more advanced and less differenti-
ated tumors. Therefore, the lack of a statistical significance we 
observed between the altered Let-7g and miR-21 expression 
and NSCLC histology could be explained by the fact that 
most of the enrolled patients were diagnosed in an advanced 
stage, where miRNA histology-related expression may be not 
specific.
Concerning the other analysed clinicopathological char-
acteristics, we did not observe any significant correlation 
between the Let-7g and miR-21 dysregulated expression and 
the clinicopathological features, including age, tumor stage, 
therapy response and smoking habit. In particular, our results 
concerning the relationship between the miR-21 expression 
and the smoking habit are in disagreement with data reported 
by Seike et al (26), who demonstrated that miR-21 expression 
is significantly higher in tumors from smokers than from 
never smokers; however, this discrepancy could be due to the 
small number of patients for whom we had smoking data. 
Interestingly, we found that Let-7g expression is significantly 
associated with lymph nodal status. We showed that most 
of the NSCLC patients with a low Let-7g expression present 
metastatic lymph nodes at diagnosis, while no substantial 
differences were observed for the patients with a high Let-7g 
expression. This result suggests an important role of Let-7g 
in NSCLC tumor progression and acquisition of metastatic 
potential and is supported by in vivo studies showing that 
ectopic Let-7g expression in NSCLC xenografts induce a 
significant decrease in tumor growth and spread (17,18).
Since the importance of EGFR and K-Ras mutation 
detection in current management of the NSCLC patients, 
we explored the relationship between their mutational status 
and Let-7g and miR-21 expression profile. In our study, the 
frequency of K-Ras mutation (20.5%) was in agreement with 
previously reported data (34,35), whereas EGFR mutation 
incidence was slightly higher (29.5%) than that reported in the 
literature for lung cancer (15-20%) (6,36-38), because many 
of the recruited patients belonged to a larger study designed 
to evaluate the EGFR TKI response. According to previously 
reported data (20,21,30,39), Let-7g expression was not corre-
lated with EGFR or K-Ras mutational status. However, several 
studies have demonstrated that Let-7g acts as a K-Ras negative 
regulator by binding to multiple sites of their 3'UTRs (40) and 
that lung cancer tissues with reduced Let-7g levels have signifi-
cantly higher K-Ras levels compared to their corresponding 
normal tissues (18,20). Therefore, it is possible that the aber-
rant expression of Let-7g and K-Ras mutations are mutually 
exclusive in NSCLC carcinogenesis with a more predominant 
effect of Let-7g dysregulation in SCCs, which show a low 
expression of this miRNA compared to the other NSCLC 
histotypes and a more prominent role of K-Ras mutations in 
ADC carcinogenesis (32,33).
Furthermore, we first demonstrated a strong and highly 
significant correlation between the high miR-21 expression 
and the presence of mutations in the codons 12 and 13 of 
K-Ras gene, suggesting a synergistic interplay between miR-21 
and K-Ras oncogenes that supports neoplastic phenotype in 
NSCLC. Based on miR-21 expression and target gene predic-
tion results, we might hypothesize an auto-regulatory loop 
between oncogenic K-Ras and miR-21 mediated by the MAPK/
ERK signalling pathway, SPRY1/SPRY2 and PDCD4 (Fig. 4). 
K-Ras mutations determine a constitutive protein activation 
with a consequent activation of the MAPK/ERK signalling 
pathway, which plays an important role in lung carcinogenesis 
by inhibiting apoptosis and promoting cell proliferation, cell 
Table V. Short-term correlations between the prognosis of the 
NSCLC patients and the Let-7 and miR-21 expression.
Characteristic PFS p-valueb OS p-valueb
  (months)a  (months)a
Let-7g
expression
 Low 18 (15-22) 0.01 20 (16-23) 0.023
 High 12   (8-16)  13   (9-17)
miR-21
expression
 Low 19 (16-23) 0.0003 21 (17-25) 0.0045
 High 11   (8-14)  13   (9-17)
aValues are shown as mean (95% CI). bp-values were assessed by the 
one-way analysis of variance (ANOVA) and significant p-values are 
in bold.
Figure 4. Auto-regulatory loop between K-Ras and miR-21. Proposed model 
showing that miR-21 potentiates the oncogenic K-Ras signalling pathway by 
promoting cell proliferation, angiogenesis and invasion and inhibits apop-
tosis through the repression of multiple tumor suppressors.
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growth, angiogenesis, invasion and metastasis (41). On the 
other hand, miR-21 modulates several components critical to 
the NSCLC pathogenesis by targeting apoptotic effectors and 
antagonists of the MAPK/ERK signalling pathway (22,25,27). 
The high miR-21 expression observed in our NSCLC patients 
might cause a decrease in SPRY1/SPRY2 expression that has 
been demonstrated to negatively regulate the MAPK/ERK 
signalling pathway and to enhance cell migration (42). In 
addition, the negative regulation of PDCD4 and Apaf-1 genes 
by miR-21 leads to apoptosis inhibition (22,27,43), as well 
as to the removal of the PDCD4 inhibitory effect on AP-1, 
which is downstream the MAPK/ERK signalling pathway 
and promotes miR-21 expression (44,45). This complex and 
auto-regulatory circuit might justify the high levels of miR-21 
expression observed in our study in the NSCLC patients 
harbouring K-Ras mutations and might have a final stimula-
tion effect on the processes that promote tumor progression 
and therapy resistance (Fig. 4).
We investigated the relationship between the differential 
Let-7g and miR-21 expression and prognosis of the NSCLC 
patients without observing any statistically significant correla-
tion. These results are in disagreement with data reported by 
other authors that support a negative prognostic role for Let-7g, 
whose downregulation has been associated with a reduced 
overall post-operative survival in NSCLC patients (18-21), 
and miR-21, whose overexpression has been associated with a 
poor prognosis irrespective of the TNM stage and lymph nodal 
status (23,26,46). However, these discrepant results could be 
due to the small number of patients with available clinical data. 
Interestingly, by restricting our analysis to the first 30 months 
of the follow-up observation, we demonstrated that the NSCLC 
patients with a high expression of either Let-7g or miR-21 show a 
highly significant shorter PFS and OS compared to the patients 
with a low expression of both these miRNAs, suggesting a 
possible negative short-term prognostic value of the evaluation 
of Let-7g and miR-21 expression.
In conclusion, our data show that Let-7g and miR-21 are 
aberrantly expressed in the NSCLC patients and that there is 
a close interplay among K-Ras, miR-21 and Let-7g in NSCLC, 
suggesting that their systematic evaluation could represent 
a useful biomarker in the molecular characterization and 
management of NSCLC patients.
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